macrolides | CMAC

macrolides

Potential for the use of macrolides in the antimicrobial therapy of severe community-acquired pneumonia in adults

This paper presents mechanism of action and antimicrobial spectrum of macrolides as well as the known acquired resistance mechanisms in the common pathogens causing community-acquired pneumonia, such as Streptococcus pneumoniae and Mycoplasma …

Four cases of resistance mutations in 23S rRNA gene in Mycoplasma pneumoniae isolated from the hospitalized military personnel

Mycoplasma pneumoniae is a bacterial pathogen cause of upper and lower respiratory tract infections, transmitted by airborne droplets, causing outbreaks of pneumonia mainly in closed groups. According with recommendations, M. pneumoniae infections …

Cardiac Toxicity of Macrolide Antibiotics

This review describes known mechanisms, possible causes of cardiac toxicity of macrolides antibiotics and the incidence of this adverse effect.

Medical Problems Associated with Bacterial Biofilms

This paper represents a review of currently available data on microbial communities and biofilms as an important clinical problem. Structure and morphology of microbial biofilm as well as stages and mechanisms of its formation, and genes and factors …

Emerging Concepts in Use of Macrolides in Pregnancy and Lactation

This paper reviews general issues of the use of antimicrobial agents in pregnant women. Currently available data on safety of macrolides during pregnancy and lactation are considered with the focus on several indications for their therapeutic and …

Potential for Use of Spiramycin in Clinical Practice

Spiramycin, natural 16-membered macrolide antibiotic, was discovered in 1954. This antimicrobial agent is at least non-inferior to and has some advantages over the currently available macrolides in spectrum of activity, pharmacological properties, …

Asthma associated with Chlamydophila pneumoniae-infection

The present open-label, randomized, comparative study of efficacy of 8-week Azithromycin therapy in mildto-moderate stable asthma included 71 patients. After evaluation for C. pneumoniae infection by serologic tests, patients where randomized into 4 …

Efficacy and Safety of Josamycin in the Treatment of Mild-to-Moderate Community-Acquired Pneumonia: Results of Multicenter Clinical Study

Multicenter prospective non-comparative open-label clinical study to assess clinical and microbiological efficacy and safety of josamycin (16-memebered macrolide) in adults with non-severe community-acquired pneumonia (CAP) was performed. Patients …

Clarithromycin: is There Potential for Clinical Use in the 21th Century?

Clarithromycin – 14-membered macrolide antibiotic that has been used in clinical practice since 1991. This review presents up-to-date data on pharmacokinetics, pharmacodynamics, drug interactions, safety profile of clarithromycin, including its novel …

Spiramycin: the classic and the present

Spiramycin is classic representative of the 16-membered macrolides, which was synthesized in 1954. Nevertheless he keeps his clinical significance due to the high activity against typical causative agents of respiratory tract, skin and soft tissues …